All News

GCA,woman

Choices in GCA

d David Liew, FRACP

There are a number of diseases where new biologic and targeted synthetic therapeutic options are coming online, and the temptation will be to consider them all equally. GCA is one of those diseases.

Read Article
puzzle.RA_.jpg

Difficult-to-treat RA: are we any closer to predicting who is at risk?

d Mrinalini Dey, MD

It is almost four years since EULAR published its definition of difficult-to-treat (D2T) rheumatoid arthritis (RA) (1). This marked a formal recognition of the group of patients who, despite the advances in pharmacological therapy for RA, remain symptomatic.

Read Article
Can we prevent psoriatic arthritis? PsA affects up to 30% of PsO patients. Understanding factors that lead to PsA helps in early interventions. Most PsA patients have preceding PsO. https://t.co/03H4YrvxMe https://t.co/efUVaccSHn

Links:

Dr. John Cush RheumNow ( View Tweet)
Summary of #EULAR2024 #ClinicalPearls JAKi have expanding disease data ✅ #GCA w #UPA ✅ Awaiting data in #SLE w #UPA & #Deucravacitinib ✅Use in #JIA ✅No new safety signals @rheumnow @eular_org

Janet Pope Janetbirdope ( View Tweet)

EULAR 2024: New drugs for RA? Abiprubart is an Abatacept distant relative, targeting T cell activation through a different target/molecular interaction (CD40/CD154). https://t.co/3wAGjfCdcN https://t.co/2YK2OeIVZK

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 - Day 1 Report https://t.co/LpYxUP8d7e https://t.co/5zwc0HsZZ8

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb & UCB. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

RheumNow’s expanded coverage of the #EULAR2024 annual meeting is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty.

Dr. John Cush RheumNow ( View Tweet)

How many #autoantibodies Does one need in #rheumatoid #arthritis Need 4 citrullinated peptides Covers off 97% of IgG CVP2 ACPAs #EULAR2024 @RheumNow @eular_org https://t.co/LNFGuFXGrC

Links:

Janet Pope Janetbirdope ( View Tweet)

Once in remission with #rituximab in #GPA How long to resize 500 mg q6 mo for 4 years? ?longer ?less #EULAR2024 @eular_org @RheumNow https://t.co/G4kU3v81je

Links:

Janet Pope Janetbirdope ( View Tweet)

Telespa - telemonitoring in AxSpA « minimal impact on disease control « never examine a patient again , never find any pathology outside of joints, remote SpAologists, no longer physicians - easy to train rheumatology nurses to do our jobs @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

PMR has distinct patterns on MRI shoulder, possibly helping diagnosis. #EULAR2024 OP0248 @RheumNow also @bmj_rmdopen https://t.co/pS5kO5OQRW where they say: "Similar to our prior findings... the target of inflammation in PMR is the outer covering of a tendon, the peritendineum" https://t.co/5pu1Xiku3h

Links:

David Liew drdavidliew ( View Tweet)
EULAR 2024 Highlights: Saturday’s Recap with RheumNow https://t.co/BlOsbr9lYB

Links:

Dr. John Cush RheumNow ( View Tweet)

#EULARBEST RCT of #upadacitinib in #GCA It works to steroid spare 15 mg > 7.5 mg in outcomes Both >>placebo Ethically PBO had slower #prednisone taper Similar to #TCZ data What to choose in GCA IL6i IL17i JAKi @eular_org @RheumNow LBA0001 https://t.co/gy0TEiHxjo

Links:

Janet Pope Janetbirdope ( View Tweet)

Does B Cell Depletion Matter? Dr. Yuz Yusof interviews Dr. Ed Vital regarding abstract OP0077 at Eular 2024 in Vienna, Austria. https://t.co/IjxGWWjoGD https://t.co/GwLjB4Z7ub

Links:

Dr. John Cush RheumNow ( View Tweet)
Telespa - telemonitoring in AxSpA « minimal impact on disease control « never examine a patient again , never find any pathology outside of joints, remote SpAologists, no longer physicians - easy to train rheumatology nurses to do our jobs @RheumNow #EULAR2025

Peter Nash drpnash ( View Tweet)

#Scleroderma #recommendations #Rayanud’s #vasculopathy #digital #ulcers CCB PDE5i IV iloprost Bosentan for Digital ulcer prevention <not approved in NA> #EULAR2024 @EUSTAR_org @RheumNow #SSc https://t.co/9c2cHAptIC

Links:

Janet Pope Janetbirdope ( View Tweet)
SHR032 chinese JAK1 inhib AS and PsA - typical efficacy and safety - looks like smells like tastes like JAK1 inhib but no zoster listed or acne, or anaemia with higher dose, 1 mace 1 vte @RheumNow #EULAR2024

Peter Nash drpnash ( View Tweet)

Duo IL17A,F #SONELOKIMAB RCT in active #PsA ACR50 around 46% Nanobody to me it looks like #Bimekizumab results So far low #fungal infections OP0195 We are over run with + IL17i RCTs in #psoriatic #arthritis Impt~market /access/risk/benefit? #EULAR2024 @eular_org @RheumNow

Janet Pope Janetbirdope ( View Tweet)

Ixokibep a small IL17Ai works in #PsA 16 wks ▶️50% had PASI 100 Fast 40-42% ACR50 Same rate of MDA Helped enthesitis also ⬆️injection site rx’n Wow! But where to use vs 2 other IL17Ai and IL17AEi LB0005 #EULAR24 @eular_org @RheumNow

Janet Pope Janetbirdope ( View Tweet)

×